Literature DB >> 12799570

Prolonged remission of HIV-associated multicentric Castelman's disease with an anti-CD20 monoclonal antibody as primary therapy.

Frédéric Marrache, Claire Larroche, Nathalie Mémain, Olivier Bouchaud, Michel Robineau, Olivier Hermine, Olivier Lortholary.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12799570     DOI: 10.1097/00002030-200306130-00023

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  Highly active antiretroviral therapy alone may be an effective treatment for HIV-associated multi-centric Castleman's disease.

Authors:  Siow Ming Lee; Simon G Edwards; Daniella N Chilton; Alan Ramsay; Robert F Miller
Journal:  Haematologica       Date:  2010-08-26       Impact factor: 9.941

Review 2.  Castleman's disease: from basic mechanisms to molecular therapeutics.

Authors:  Hazem E El-Osta; Razelle Kurzrock
Journal:  Oncologist       Date:  2011-03-25

3.  Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.

Authors:  Xinping Zhou; Juying Wei; Yinjun Lou; Gaixiang Xu; Min Yang; Hui Liu; Liping Mao; Hongyan Tong; Jie Jin
Journal:  Front Med       Date:  2017-04-03       Impact factor: 4.592

4.  The Importance of Early Recognition of KSHV-Mediated Syndromes: A Case Report.

Authors:  Nathaniel J Spezia-Lindner; Divya Kondapi; Andrew R DiNardo; Ramya Ramaswami; Elizabeth Chiao; Eva H Clark
Journal:  Am J Med       Date:  2021-05-11       Impact factor: 5.928

5.  A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy.

Authors:  Lorenzo Falchi; Daniela Capello; Barbara Palumbo; Annamaria Rauco; Rita Emili; Michele Cianciulli; Roberta Pace; Vincenzo Capparella; Fabrizio Liberati; Anna Marina Liberati
Journal:  Eur J Haematol       Date:  2007-10-01       Impact factor: 2.997

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.